Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.39 |
| ▸ | TACR1 | P25103 | 4/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.37 |
| ▸ | DRD4 | P21917 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.36 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5158660 | 0.93 | TACR1 (0.39) | MEN1KMT2AL3MBTL1KDM4ESIGMAR1 | |
| SCHEMBL5159284 | 0.92 | SIGMAR1 (0.40) | KDM4ESIGMAR1TACR1TMEM97 | |
| SCHEMBL6482708 | 0.91 | SIGMAR1 (0.41) | MEN1KMT2AKDM4ESIGMAR1TACR1 | |
| SCHEMBL5162344 | 0.90 | SIGMAR1 (0.39) | MEN1KMT2AKDM4ESIGMAR1TACR1 | |
| SCHEMBL5156763 | 0.90 | TACR3 (0.40) | SIGMAR1TACR1DRD4DRD3 | |
| SCHEMBL5174357 | 0.90 | SIGMAR1 (0.39) | KDM4ESIGMAR1TACR1TMEM97 | |
| SCHEMBL5158719 | 0.90 | KDM4E (0.41) | KDM4ESIGMAR1TACR1TMEM97 | |
| SCHEMBL5161336 | 0.89 | KMT2A (0.42) | MEN1KMT2ASIGMAR1TACR1KCNH2 | |
| SCHEMBL5161802 | 0.89 | TACR1 (0.40) | KDM4ESIGMAR1TACR1TMEM97 | |
| SCHEMBL5156675 | 0.89 | TACR1 (0.47) | MEN1KMT2ASIGMAR1TACR1DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050256164-A1 | NK1 and NK3 antagonists | PFIZER INC | 2005-11-17 | — | — | US | claimed |
| EP-1748984-A1 | PIPERIDINE DERIVATIVES AS NK1 AND NK3 ANTAGONISTS | Pfizer Products Inc. (US) | 2007-02-07 | — | — | EP | disclosed |
| WO-2005110987-A1 | PIPERIDINE DERIVATIVES AS NK1 AND NK3 ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2005-11-24 | — | — | WO | disclosed |
| US-20050256164-A1 | NK1 and NK3 antagonists | PFIZER INC | 2005-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256164-A1 | NK1 and NK3 antagonists | TAC3, TACR1, TACR2 | MEN1 786/4885KMT2A 1384/4885L3MBTL1 4022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.